A Phase 3 interventional study of Telmisartan80mg+Amlodipine5mg and amlodipine 5mg in Hypertension, sponsored by Boehringer Ingelheim. Completed at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 44th largest by enrollment of the 74 interventional ones that give a count, is one of 8 that started in 2010, is one of 43 in phase 3, and was the 55th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 48 more countries
Ages 18+
By country, each count listing its studies:
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 324 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 381 across the 74 interventional studies, 3,252 across the 48 observational. Of the 120 that completed or were terminated, 41 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 122 studies in Hypertension by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this trial is to demonstrate that the fixed-dose combination of telmisartan 80mg plus amlodipine 5mg (T80/A5) is superior to amlodipine 5mg (A5) in reducing seated trough diastolic blood pressure (DBP) at 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
combination therapy
Drug: Telmisartan80mg+Amlodipine5mg
Monotherapy
Drug: amlodipine 5mg · Drug: Telmisartan80mg+Amlodipine 5mg
combination therapy
monotherapy
combination therapy
Change From Baseline in DBP After 8 Weeks of Treatment
Seated trough DBP after 8 weeks or last observation carried forward (LOCF). Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.
Time frame: Baseline and 8 weeks
Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients
Seated trough DBP after 8 weeks or LOCF in Chinese patients. Analysis will be adjusted for treatment and baseline measurement of endpoint.
Time frame: Baseline and 8 weeks
Change From Baseline in SBP After 8 Weeks of Treatment
Seated trough SBP after 8 weeks or LOCF. Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.
Time frame: Baseline and 8 weeks
DBP and SBP Control and Response After 8 Weeks of Treatment
DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.
Time frame: Baseline and 8 weeks
Number of Patients in Blood Pressure Categories Over Time
BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.
Time frame: 8 weeks
Change From Baseline in DBP After 4 Weeks of Treatment
Seated trough DBP after 4 weeks.
Time frame: Baseline and 4 weeks
Change From Baseline in SBP After 4 Weeks of Treatment
Seated trough SBP after 4 weeks.
Time frame: Baseline and 4 weeks
DBP and SBP Control and Response After 4 Weeks of Treatment
DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.
Time frame: Baseline and 4 weeks
Number of Patients in Blood Pressure Categories at 4 Weeks
BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.
Time frame: 4 weeks
Clinically Relevant Abnormalities for Physical Examination, Pulse Rate, Laboratory Parameters and ECG.
Clinically relevant abnormalities for Physical examination, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
Time frame: From drug administration until end of treatment plus one day
| Milestone | A5 Alone | T80/A5 |
|---|---|---|
| Started | 164 | 160 |
| Completed | 159 | 158 |
| Not completed | 5 | 2 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Other | 1 | 0 |
Seated trough DBP after 8 weeks or last observation carried forward (LOCF). Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.
| mmHg | A5 Alone | T80/A5 |
|---|---|---|
| Change From Baseline in DBP After 8 Weeks of Treatment | -10.19 ± 0.93 | -12.38 ± 0.95 |
Seated trough DBP after 8 weeks or LOCF in Chinese patients. Analysis will be adjusted for treatment and baseline measurement of endpoint.
| mmHg | A5 Alone | T80/A5 |
|---|---|---|
| Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients | -8.85 ± 0.63 | -10.77 ± 0.64 |
Seated trough SBP after 8 weeks or LOCF. Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.
| mmHg | A5 Alone | T80/A5 |
|---|---|---|
| Change From Baseline in SBP After 8 Weeks of Treatment | -11.66 ± 1.30 | -16.15 ± 1.33 |
DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.
| Number of participants | A5 Alone | T80/A5 |
|---|---|---|
| DBP control | 85 | 112 |
| SBP control | 100 | 119 |
| DBP response | 101 | 124 |
| SBP response | 120 | 131 |
BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.
| Number of participants | A5 Alone | T80/A5 |
|---|---|---|
| BP optimal | 7 | 11 |
| BP normal | 33 | 36 |
| BP high-normal | 32 | 53 |
| Grade 1 hypertension | 69 | 48 |
| Grade 2 hypertension | 15 | 5 |
| Grade 3 hypertension | 3 | 2 |
Seated trough DBP after 4 weeks.
| mmHg | A5 Alone | T80/A5 |
|---|---|---|
| Change From Baseline in DBP After 4 Weeks of Treatment | -7.51 ± 6.80 | -9.41 ± 7.26 |
Seated trough SBP after 4 weeks.
| mmHg | A5 Alone | T80/A5 |
|---|---|---|
| Change From Baseline in SBP After 4 Weeks of Treatment | -8.19 ± 11.45 | -12.10 ± 11.68 |
DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.
| Number of participants | A5 Alone | T80/A5 |
|---|---|---|
| DBP control | 71 | 95 |
| SBP control | 91 | 103 |
| DBP response | 87 | 108 |
| SBP response | 108 | 124 |
BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.
| Number of participants | A5 Alone | T80/A5 |
|---|---|---|
| BP optimal | 1 | 7 |
| BP normal | 20 | 26 |
| BP high-normal | 35 | 44 |
| Grade 1 hypertension | 81 | 62 |
| Grade 2 hypertension | 17 | 15 |
| Grade 3 hypertension | 5 | 1 |
Clinically relevant abnormalities for Physical examination, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
| participants | A5 Alone | T80/A5 |
|---|---|---|
| Atrial fibrilation | 0 | 1 |
| Myocardial ischaemia | 1 | 0 |
| Blood glucose increased | 1 | 4 |
| Protein urine present | 2 | 1 |
| Alanine aminotransferase increased | 0 | 1 |
| Blood creatinine phosphokinase increased | 1 | 0 |
| Blood creatinine increased | 0 | 1 |
| Blood glucose abnormal | 1 | 1 |
| Heart rate increased | 0 | 1 |
Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A5 Alone | — | 0/164 (0%) | 0/164 (0%) |
| T80/A5 | — | 0/160 (0%) | 0/160 (0%) |
| Age, Continuous(Years) | A5 Alone | T80/A5 | Total |
|---|---|---|---|
| Mean | 52.4 ± 9.7 | 52.4 ± 8.7 | 52.4 ± 9.2 |
| Sex: Female, Male(Participants) | A5 Alone | T80/A5 | Total |
|---|---|---|---|
| Female | 71 | 78 | 149 |
| Male | 88 | 77 | 165 |
| Diastolic blood pressure (DBP)(mmHg) | A5 Alone | T80/A5 | Total |
|---|---|---|---|
| Mean | 97.84 ± 6.43 | 97.21 ± 5.46 | 97.53 ± 5.97 |
| Systolic blood pressure (SBP)(mmHg) | A5 Alone | T80/A5 | Total |
|---|---|---|---|
| Mean | 146.27 ± 11.15 | 146.44 ± 12.20 | 146.35 ± 11.66 |
The record gives a start of Jul 2010 and a primary completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.